Cargando…

Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study

INTRODUCTION: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive deterioration in cognition, memory and activities of daily living. Selective blockade of serotonin-6 (5-HT(6)) receptors, which are exclusively localized to the central nervous system, is reported to...

Descripción completa

Detalles Bibliográficos
Autores principales: Nirogi, Ramakrishna, Goyal, Vinod Kumar, Benade, Vijay, Subramanian, Ramkumar, Ravula, Jyothsna, Jetta, Satish, Shinde, Anil, Pandey, Santosh Kumar, Jayarajan, Pradeep, Jasti, Venkat, Cummings, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588135/
https://www.ncbi.nlm.nih.gov/pubmed/35908254
http://dx.doi.org/10.1007/s40120-022-00390-4
_version_ 1784814060979617792
author Nirogi, Ramakrishna
Goyal, Vinod Kumar
Benade, Vijay
Subramanian, Ramkumar
Ravula, Jyothsna
Jetta, Satish
Shinde, Anil
Pandey, Santosh Kumar
Jayarajan, Pradeep
Jasti, Venkat
Cummings, Jeffrey
author_facet Nirogi, Ramakrishna
Goyal, Vinod Kumar
Benade, Vijay
Subramanian, Ramkumar
Ravula, Jyothsna
Jetta, Satish
Shinde, Anil
Pandey, Santosh Kumar
Jayarajan, Pradeep
Jasti, Venkat
Cummings, Jeffrey
author_sort Nirogi, Ramakrishna
collection PubMed
description INTRODUCTION: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive deterioration in cognition, memory and activities of daily living. Selective blockade of serotonin-6 (5-HT(6)) receptors, which are exclusively localized to the central nervous system, is reported to play an important role in learning and memory. Masupirdine is a potent and selective 5-HT(6) receptor antagonist with pro-cognitive properties in animal models of cognition. METHODS: The efficacy and safety of masupirdine were evaluated in patients with moderate AD concurrently treated with donepezil and memantine. A total of 564 patients were randomized in a 1:1:1 ratio. The study consisted of a 26-week double-blind treatment period. The primary efficacy outcome was the 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog 11). Changes from baseline were analyzed using a mixed effects model for repeated measures (MMRM). In exploratory post hoc analyses, patients were subdivided based on the use of memantine dosage forms and memantine plasma concentrations, to evaluate the impact of memantine on the efficacy of masupirdine. RESULTS: In an exploratory post hoc analysis, less worsening in cognition (ADAS-Cog 11 scores) was observed with masupirdine treatment as compared with placebo in patients whose trough memantine plasma concentrations were ≤ 100 ng/mL. CONCLUSIONS: Although prespecified study endpoints of the phase 2 study were not met, these exploratory post hoc subgroup observations are hypothesis-generating and suggest that the efficacy of masupirdine was adversely affected by concurrent therapy with memantine. Further assessment of masupirdine to determine its potential role as a treatment option for cognitive deficits associated with AD is warranted. TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov (NCT02580305).
format Online
Article
Text
id pubmed-9588135
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-95881352022-11-29 Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study Nirogi, Ramakrishna Goyal, Vinod Kumar Benade, Vijay Subramanian, Ramkumar Ravula, Jyothsna Jetta, Satish Shinde, Anil Pandey, Santosh Kumar Jayarajan, Pradeep Jasti, Venkat Cummings, Jeffrey Neurol Ther Original Research INTRODUCTION: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive deterioration in cognition, memory and activities of daily living. Selective blockade of serotonin-6 (5-HT(6)) receptors, which are exclusively localized to the central nervous system, is reported to play an important role in learning and memory. Masupirdine is a potent and selective 5-HT(6) receptor antagonist with pro-cognitive properties in animal models of cognition. METHODS: The efficacy and safety of masupirdine were evaluated in patients with moderate AD concurrently treated with donepezil and memantine. A total of 564 patients were randomized in a 1:1:1 ratio. The study consisted of a 26-week double-blind treatment period. The primary efficacy outcome was the 11-item cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog 11). Changes from baseline were analyzed using a mixed effects model for repeated measures (MMRM). In exploratory post hoc analyses, patients were subdivided based on the use of memantine dosage forms and memantine plasma concentrations, to evaluate the impact of memantine on the efficacy of masupirdine. RESULTS: In an exploratory post hoc analysis, less worsening in cognition (ADAS-Cog 11 scores) was observed with masupirdine treatment as compared with placebo in patients whose trough memantine plasma concentrations were ≤ 100 ng/mL. CONCLUSIONS: Although prespecified study endpoints of the phase 2 study were not met, these exploratory post hoc subgroup observations are hypothesis-generating and suggest that the efficacy of masupirdine was adversely affected by concurrent therapy with memantine. Further assessment of masupirdine to determine its potential role as a treatment option for cognitive deficits associated with AD is warranted. TRIAL REGISTRATION: The study was registered at ClinicalTrials.gov (NCT02580305). Springer Healthcare 2022-07-31 /pmc/articles/PMC9588135/ /pubmed/35908254 http://dx.doi.org/10.1007/s40120-022-00390-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Nirogi, Ramakrishna
Goyal, Vinod Kumar
Benade, Vijay
Subramanian, Ramkumar
Ravula, Jyothsna
Jetta, Satish
Shinde, Anil
Pandey, Santosh Kumar
Jayarajan, Pradeep
Jasti, Venkat
Cummings, Jeffrey
Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
title Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
title_full Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
title_fullStr Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
title_full_unstemmed Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
title_short Effect of Concurrent Use of Memantine on the Efficacy of Masupirdine (SUVN-502): A Post Hoc Analysis of a Phase 2 Randomized Placebo-Controlled Study
title_sort effect of concurrent use of memantine on the efficacy of masupirdine (suvn-502): a post hoc analysis of a phase 2 randomized placebo-controlled study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588135/
https://www.ncbi.nlm.nih.gov/pubmed/35908254
http://dx.doi.org/10.1007/s40120-022-00390-4
work_keys_str_mv AT nirogiramakrishna effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT goyalvinodkumar effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT benadevijay effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT subramanianramkumar effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT ravulajyothsna effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT jettasatish effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT shindeanil effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT pandeysantoshkumar effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT jayarajanpradeep effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT jastivenkat effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy
AT cummingsjeffrey effectofconcurrentuseofmemantineontheefficacyofmasupirdinesuvn502aposthocanalysisofaphase2randomizedplacebocontrolledstudy